Skip to main content

Latest stock market podcasts

From the helm: Immutep’s (ASX:IMM) Executive Director & CEO Marc Voigt

Sophia Mavridis
April 6, 2022

In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.

Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.

In this video Marc discusses:

  • (0:40) What IMM does and its key strength in the market
  • (1:27) The impact of the FDA’s recent feedback on its lead product
  • (2:53) IMM’s collaborations with big pharma names like Pfizer & Merck
  • (4:03) When to expect data from its current clinical trials
  • (5:10) What’s coming up for IMM

Note: This interview was filmed on 22 March 2022.

Market Update 19 March

Bell Direct
March 19, 2020

Morning Bell 18 March

Bell Direct
March 18, 2020

Morning Bell 17 March

Bell Direct
March 17, 2020

Market Update 16 March

Bell Direct
March 16, 2020

Weekly Wrap 13 March

Bell Direct
March 13, 2020

Morning Bell 12 March

Bell Direct
March 12, 2020

Morning Bell 11 March

Bell Direct
March 11, 2020

Morning Bell 10 March

Bell Direct
March 10, 2020

Weekly Wrap 6 March

Bell Direct
March 6, 2020

Morning Bell 5 March

Bell Direct
March 5, 2020

Market Update 4 March

Bell Direct
March 4, 2020

Morning Bell 3 March

Bell Direct
March 2, 2020